SEARCH

SEARCH BY CITATION

References

  • Almeida L, Soares-da-Silva P. (2003) Safety, tolerability and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic agent, during first administration to humans. Drugs R&D 4:269284.
  • Almeida L, Soares-da-Silva P. (2004) Safety, tolerability, and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans. J Clin Pharmacol 44:906918.
  • Almeida L, Soares-da-Silva P. (2007) Eslicarbazepine acetate (BIA 2-093). Neurotherapeutics 4:8896.
  • Almeida L, Falcão A, Maia J, Mazur D, Gellert M, Soares-da-Silva P. (2005) Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2-093) in healthy elderly and young subjects. J Clin Pharmacol 45:10621066.
  • Almeida L, Falcão A, Maia J, Vaz-da-Silva M, Soares E, Soares-da-Silva P. (2006a) Steady-state pharmacokinetics of once-daily and twice-daily regimens of eslicarbazepine acetate (BIA 2-093) in healthy subjects. AES Proc Epilepsia 47(Suppl. 4):154, Abstarct 2.102.
  • Almeida L, Vaz-da-Silva M, Falcão A, Maia J, Soares E, Soares-da-Silva P. (2006b) Effect of eslicarbazepine acetate (BIA 2-093) on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Proceedings of the 7th European Congress on Epileptology, Helsinki; Abstract Book.
  • Almeida L, Potgieter JH, Maia J, Potgieter MA, Mota F, Soares-da-Silva P. (2008) Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment. Eur J Clin Pharmacol 64:267273.
  • Almeida L, Bialer M, Soares-da-Silva P. (2009) Eslicarabzepine acetate. In Shorvon S, Perucca E, Engel J (Eds) The epilepsy treatment of epilepsy. 3rd ed. Wiley-Blackwell, Oxford, pp. 485498.
  • Almeida L, Nunes T, Sicard E, Rocha J-F, Falcão A, Brunet J-S, Lefevbvre M, Soares-da-Silva P. (2010) Pharmacokinetic interaction study between eslicarbazepine acetate and lamotrigine in healthy subjects. Acta Neurol Scand 121:257264.
  • Alves G, Figueiredo I, Falcão A, Castel-Branco M, Caramona M, Soares Da-Silva P. (2008) Stereoselective disposition of S- and R-licarbazepine in mice. Chirality 20:796804.
  • Amidon GL, Lennernas H, Shah VP, Crison JR. (1995) A theoretical basis for a bioequivalence drug classification; the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12:413420.
  • Ben-Menachem E, Gabbai AA, Hufnagel A, Maia J, Almeida L, Soares-da-Silva P. (2010) Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy. Epilepsy Res 89:278285.
  • Bialer M (2002) Oxcarbazepine: chemistry, biotransformation and pharmacokinetics. In Levy RH, Mattson RH, Meldrum BS, Perucca E (Eds) Antiepileptic drugs. 5th ed. Lippincott Williams & Wilkins Publishers, New York, pp. 459465.
  • Bialer M. (2006) New antiepileptic drugs that are second generation to existing antiepileptic drugs. Expert Opin Investig Drugs 15:637647.
  • Bialer M, White HS. (2010) Key factors in the discovery and development of new antiepileptic drugs (AEDs). Nat Rev Drug Discov 29:6883.
  • Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T. (2004) Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII). Epilepsy Res 61:148.
  • Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T. (2007) Progress report on new antiepileptic drugs: a summary of the Eighth Eilat Conference (EILAT VIII). Epilepsy Res 73:152.
  • Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. (2009) Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res 83:143.
  • Boxenbaum H, Battle M. (1995) Effective half-life in clinical pharmacology. Clin Pharmacol 35:763766.
  • Elger C, Bialer M, Cramer JA, Maia J, Almeida L, Soares-da-Silva P. (2007) Eslicarbazepine acetate: a double-blind, add-on placebo-controlled exploratory trial in adult patients with partial-onset seizures. Epilepsia 48:497503.
  • Elger C, Halas P, Maia J, Almeida L, Soares-da-Silva P. (2009) Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study. Epilepsia 50:454463.
  • Faigle JW, Menge GP. (1990) Pharmacokinetics and metabolic features of oxcarbazepine and their clinical significance: comparison with carbamazepine. Int J Clin Psychopharmacol 5:7382.
  • Falcão A, Maia J, Almeida L, Mazur D, Gellert M, Soares-da-Silva P. (2007) Effect of gender on the pharmacokinetics of eslicarbazepine acetate (BIA 2-093), a new voltage-gated sodium channel blocker. Biopharm Drug Dispos 28:249256.
  • Falcão A, Fuseau E, Nunes T, Almeida L, Soares-da-Silva P. (2012) Pharmacokinetics, drug interactions and exposure-response relationship of eslicarbazepine acetate in adult patients with partial-onset seizures. CNS Drugs 26:7991.
  • Fattore C, Cipolla G, Gatti G, Limido GL, Strum Y, Bernasconi C, Perucca E. (1999) Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. Epilepsia 40:783787.
  • Flesch G. (2004) Overview of the clinical pharmacokinetics of oxcarbazepine. Clin Drug Investig 24:185203.
  • Flesch G, Czendik C, Ehrhart F, Hell F, Lloyd P. (1999) Pharmacokinetics of the two enantiomers of the monohydroxy derivative of oxcarbazepine in man. Eur J Pharm Sci 8:xxii Abstract 89.
  • Flesch G, Czendlik C, Renard D, Lloyd P. (2011) Pharmacokinetics of the monohydroxy derivative of oxcarbazepine and its two enantiomers after a single intravenous dose given as racemate compared with a single oral dose of oxcarbazepine. Drug Metab Dipsosit 39:11031110.
  • Fontes-Ribeiro C, Nunes T, Falcão A, Neta C, Lima R, Tavares S, Almeida L, Macedo T, Soares-da-Silva P. (2005) Eslicarbazepine acetate (BIA 2-093): Relative bioavailability and bioequivalence of 50 mg/mL oral suspension and 200 mg and 800 mg tablet formulations. Drugs R D 6:253260.
  • Fortuna A, Sousa J, Alves G, Falcao A, Soares-da-Silva P. (2010) Development and validation of an HPLC-UV method for the simultaneous quantification of carbamazepine, oxcarbazepine, eslicarbazepine acetate and their main metabolites in human plasma. Anal Bioanal Chem 397:16051615.
  • Gil-Nagel A, Lopes-Lima J, Almeida L, Maia J, Soares-da-Silva P. (2009) Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures. Acta Neurol Scand 120:281287.
  • Hainzl D, Parada A, Soares-da-Silva P. (2001) Metabolism of two new antiepileptic drugs and their principal metabolites S(+)- and R(−)-10,11-dihydro-10-hydroxy carbamazepine. Epilepsy Res 44:197206.
  • Kharidia J, Maier G, Versavel M, Blum D, Maia J, Soares-da-Silva P. (2010) CSF and plasma pharmacokinetics of eslicarbazepine acetate and oxcarbazepine in healthy subjects. AES Annual Meeting, San Antonio, Abstract.
  • Kwan KC, Bohidar NR, Hwang SS. (1984) Estimation of an effective half-life. In Benet LZ, Levy G, Ferraiolo B (Eds) Pharmacokinetics: a modern view. Plenum Press, New York, pp. 147162.
  • Lakehal F, Wurden CJ, Kalhorn TF, Levy RH. (2002) Carbamazepine and oxcarbazepine decrease phenytoin metabolism through inhibition of CYP2C19. Epilepsy Res 52:7982.
  • Loureiro AI, Fernanades-Lopes C, Bonifacio MJ, Wright LC, Soares-da-Silva P. (2011a) Hepatic UDP-glucuronosyltransferase responsible for eslicarbazepine glucuronidation. Drug Meta Disposit 39:14861494.
  • Loureiro AI, Fernandes-Lopes C, Wright LC, Soares-da-Silva P. (2011b) Development and validation of an enantioselective liquid-chromatography/tandem mass spectrometry method for the separation and quantification of eslicarbazepine acetate, eslicarbazepine, R-licarbazepine and oxcarbazepine in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 879:26112618.
  • Maia J, Almeida L, Vaz-da-Silva M, Soares E, Tavares S, Falcão A, Soares-da-Silva P. (2005) Effect of eslicarbazepine acetate on the steady-state pharmacokinetics of digoxin in healthy subjects. Epilepsia 46:17879 (abstract).
  • Maia J, Almeida L, Falcão A, Soares E, Mota F, Potgieter JH, Potgieter MA, Soares-da-Silva P. (2008) Effect of renal impairment on the pharmacokinetics of eslicarbazepine acetate. Int J Clin Pharmacol Ther 46:119130.
  • Marchi N, Guiso G, Rizzi M, Pirker S, Novak K, Czech T, Baumgartner C, Janigro D, Caccia S, Vezzani A. (2005) A pilot study on brain-to-plasma partition of 10,11-dyhydro-10-hydroxy-5H-dibenzo(b,f)azepine-5-carboxamide and MDR1 brain expression in epilepsy patients not responding to oxcarbazepine. Epilepsia 46:16131619.
  • Mauro VF. (1993) Clinical pharmacokinetics and practical applications of simvastatin. Clin Pharmacokinet 24:195202.
  • Nunes T, Minciu I, Almeida L, Magureanu SA, Falcão A, Butoianu N, Soares-da-Silva P. (2007) Pharmacokinetics of eslicarbazepine acetate in children and adolescents with epilepsy. Proceedings of the 27th International Epilepsy Congress, Singapore 2007; Abstract Book.
  • Nunes T, Sicard E, Almeida L, Falcão A, Rocha J-F, Brunet J-S, Lefevre M, Soares-da-Silva P. (2010) Pharmacokinetic interaction study between eslicarbazepine acetate and topiramate in healthy subjects. Curr Med Res Opin 6:13551362.
  • Perucca E, Elger C, Halasz P, Falcao A, Almeida L, Soares-da-Silva P. (2011) Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures. Epilepsy Res 96:132139.
  • Rocha J-F, Vaz-da-Silva M, Almeida L, Falcão A, Nune T, Santos A-T, Martins F, Fontes-Ribeiro C, Soares-da-Silva P. (2009) Effect of eslicarbazepine acetate on the pharmacokinetics a of metformin in healthy subjects. Int J Clin Pharmacol Ther 47:255261.
  • Rowland M, Tozer T. (2010) Clinical pharmacokinetics and pharmacodynamics. 4th ed. Walter Kluwer, Philadelphia, PA, pp. 203204.
  • Sahin S, Benet LZ. (2008) The operational multiple-dosing half-life: a key to defining drug accumulation in patients and to designing extended release dosage forms. Pharm Res 25:28692877.
  • Schutz H, Feldmann KF, Faigle JW, Kiemler H-P, Winkler T. (1986) The metabolism of 14C-oxcarbazepine in humans. Xenobiotica 8:769778.
  • Vaz-da-Silva M, Nunes T, Soares E, Rocha JF, Tavares S, Falcão A, Almeida L, Soares-da-Silva P. (2005) Eslicarbazepine acetate pharmacokinetics after single and repeated doses in healthy subjects. Epilepsia 46:191 (abstract).
  • Vaz-da-Silva M, Costa R, Soares E, Maia J, Falcão A, Almeida L, Soares-da-Silva P. (2009) Effect of eslicarbazepine acetate on the pharmacokinetics of digoxin in healthy subjects. Fundam Clin Pharmacol 23:509514.
  • Vaz-da-Silva M, Almeida L, Falcão A, Soares E, Maia J, Nune T, Soares-da-Silva P. (2010) Effect of eslicarbazepine acetate on steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three stage, open-label, multiple-dose, single-period study. Clin Ther 32:179192.
  • Volosov A, Xiaodong S, Perucca E, Yagen B, Sintov A, Bialer M. (1999) Enantioselective pharmacokinetics of 10-hydroxycarbazepine after oral administration of oxcarbazepine to healthy Chinese subjects. Clin Pharmacol Ther 66:547553.
  • Wen Z, Martin DE, Bullock P, Lee KH, Smith PC. (2007) Glucuronidation of anti-HIV drug candidate bevirimat: identification of human UDP-glucuronosyltransferases and species differences. Drug Metab Disposit 35:440448.
  • Wu C-Y, Benet LZ. (2005) Predicting drug disposition via application of BCS: Transport/absorption elimination interplay and development of biopharmaceutics drug disposition classification system. Pharm Res 22:1123.
  • Zenser TV, Lakshmi VM, Davis BB. (1999) Human and Escherichia coli beta-glucuronidase hydrolysis of glucuronide conjugates of benzidine and 4-aminobiphenyl, and their hydroxy metabolites. Drug Metab Disposit 27:10641067.